- Home
- DLY vs DAWN Comparison
DLY vs DAWN Comparison
Compare DLY & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DLY
- DAWN
- Stock Information
- Founded
- DLY 2019
- DAWN 2018
- Country
- DLY United States
- DAWN United States
- Employees
- DLY N/A
- DAWN N/A
- Industry
- DLY Investment Managers
- DAWN Biotechnology: Pharmaceutical Preparations
- Sector
- DLY Finance
- DAWN Health Care
- Exchange
- DLY Nasdaq
- DAWN Nasdaq
- Market Cap
- DLY 744.3M
- DAWN 624.8M
- IPO Year
- DLY N/A
- DAWN 2021
- Fundamental
- Price
- DLY $15.13
- DAWN $7.29
- Analyst Decision
- DLY
- DAWN Strong Buy
- Analyst Count
- DLY 0
- DAWN 7
- Target Price
- DLY N/A
- DAWN $27.86
- AVG Volume (30 Days)
- DLY 215.9K
- DAWN 1.4M
- Earning Date
- DLY 01-01-0001
- DAWN 10-29-2025
- Dividend Yield
- DLY 8.93%
- DAWN N/A
- EPS Growth
- DLY N/A
- DAWN N/A
- EPS
- DLY N/A
- DAWN N/A
- Revenue
- DLY N/A
- DAWN $187,638,000.00
- Revenue This Year
- DLY N/A
- DAWN $12.69
- Revenue Next Year
- DLY N/A
- DAWN $48.51
- P/E Ratio
- DLY N/A
- DAWN N/A
- Revenue Growth
- DLY N/A
- DAWN 2190.50
- 52 Week Low
- DLY $13.26
- DAWN $5.64
- 52 Week High
- DLY $15.95
- DAWN $16.76
- Technical
- Relative Strength Index (RSI)
- DLY 37.64
- DAWN 51.50
- Support Level
- DLY $15.11
- DAWN $6.70
- Resistance Level
- DLY $15.26
- DAWN $8.28
- Average True Range (ATR)
- DLY 0.13
- DAWN 0.36
- MACD
- DLY -0.01
- DAWN 0.04
- Stochastic Oscillator
- DLY 29.76
- DAWN 32.82
About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest
DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.